Stockholm, Sweden, August 19, 2022 – Inify Laboratories AB (“Inify”) has been notified that the following transaction has been completed by a close associate to a primary insider in Inify: […]
STOCKHOLM – August 17 2022 – Inify Laboratories, a company providing fully digitalized pathology laboratory services for cancer diagnostics, listed in June 2022 on the Euronext Growth in Oslo, is on […]
STOCKHOLM – July 28, 2022 – Inify Laboratories AB (publ) hereby invites its shareholders to en Extraordinary General Meeting on August 30th, 2022. Please find attached the invitation including agenda […]
STOCKHOLM – July 28, 2022 – Inify Laboratories AB (publ) hereby invites its shareholders to en Extraordinary General Meeting on August 30th, 2022. Please find attached the invitation including agenda […]
Stockholm, June 29th 2022 Inify Laboratories announces the addition of specialized medical competence to the company’s management team and organization. “We warmly welcome Dr. Claes Lind to the role as […]
“Today I’m truly thrilled to announce that Inify Laboratories is admitted to trading on Euronext Growth Oslo, less than 5 months after we became independent. With solid funding of NOK […]
Stockholm, June 16, 2022 Oslo Børs has decided to admit Inify Laboratories AB to trading. It is stipulated that the company prior to the first day of trading must satisfy […]
STOCKHOLM – May 30th, 2022 Inify Laboratories AB has decided to extend the Subscription Period in the ongoing Subsequent Offering to 3 June 2022 at 16:30 hours (CEST). As a […]
STOCKHOLM – 9 maj 2022 Inify Laboratories har hållit en extra bolagsstämma den 9 maj 2022. Bifogat finns en sammanfattning av de beslut som fattades vid den extra bolagsstämman. Vänligen […]
STOCKHOLM – 11 april 2022 Inify Laboratories bjuder härmed in sina aktieägare till en extra bolagsstämma den 9 maj 2022. Bifogat finns kallelse inklusive dagordning och information om hur man […]